A 5.1-month improvement in median progression-free survival — from 6.4 months on pembrolizumab monotherapy to 11.5 months on the high-dose fianlimab–cemiplimab combination — failed to cross the threshold of statistical significance, with a p-value of 0.0627 against a pre-specified boundary that required something closer to 0.05. That gap between clinical numerics and statistical validity is the central tension in this readout, and it matters enormously for how the LAG-3 inhibitor class is interpreted heading into the next competitive round.
The trial enrolled 1,546 patients across four arms, giving it sufficient power to detect a meaningful PFS difference. The hazard ratio of 0.845 for the high-dose combination is directionally favorable but carries a confidence interval that clips 1.0 at its upper bound (0.709–1.008), which is precisely the kind of result that leaves regulators with no clear path forward and investigators without a pivotal win. The low-dose arm performed worse — HR 0.931, p=0.4661 — effectively ruling out that dose level entirely. No new safety signals emerged, which preserves the combination’s tolerability profile but does nothing to rescue the primary endpoint.
What keeps fianlimab’s program alive is the ongoing Phase 3 head-to-head trial against Opdualag, Bristol-Myers Squibb’s approved LAG-3 plus PD-1 combination. That trial reframes the scientific question: rather than asking whether dual LAG-3/PD-1 blockade beats PD-1 alone — a question now answered with an unsatisfying “almost” — it asks which LAG-3 combination is superior. Opdualag’s own approval in first-line melanoma was based on a PFS improvement over nivolumab monotherapy, so the competitive bar is set by an already-validated LAG-3 mechanism. Regeneron is essentially conceding the monotherapy comparison and betting the program on differentiation within the class.
The detail to track now is the overall survival data from this failed PFS trial. A numeric PFS advantage this size, even without significance, occasionally translates into an OS signal at later follow-up — and a positive OS read could resurrect regulatory conversations that the PFS miss has presently foreclosed. If OS also trends without hitting significance, the high-dose fianlimab program’s only viable path to market runs entirely through the Opdualag comparison.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
